Short answer
BioAge Labs, Inc. (BIOA) filed an 8-K current report with the SEC on October 2, 2026 reporting Item 8.01 (Other Events). First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study.
BioAge Labs, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study
- Approximately 180 participants across three arms, testing BGE-102 monotherapy and combination use with anti-VEGF therapy
- Primary endpoint: best-corrected visual acuity change at week 12 after once-daily 90 mg dosing
- Topline results expected in the second half of 2027, a potential catalyst for BGE-102’s retinal disease strategy
- Results may guide development in other NLRP3-driven diseases, including geographic atrophy, but remain subject to clinical and regulatory risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BioAge Labs, Inc. 8-K filings
Get the next BIOA 8-K as it lands
Follow BIOA for push alerts, or ask the research agent what this filing means.